Get started
Author

Emma J. Langley

Observed names: E Langley, Emma Langley
OpenAlex ID: A5086614659
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
2017 · Ariella B. Hanker, Joan T. Garrett, et al. · Clinical Cancer Research · 98
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity
2011 · Jianying Dong, Arlene Sereno, et al. · mAbs · 80
Combination of Two Insulin-Like Growth Factor-I Receptor Inhibitory Antibodies Targeting Distinct Epitopes Leads to an Enhanced Antitumor Response
2010 · Jianying Dong, Stephen J. Demarest, et al. · Molecular Cancer Therapeutics · 68
Stable IgG-like Bispecific Antibodies Directed toward the Type I Insulin-like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-tumor Activity
2010 · Jianying Dong, Arlene Sereno, et al. · Journal of Biological Chemistry · 39
PDF
Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
2015 · Silvia Park, Emma Langley, et al. · Oncotarget · 10
PDF
Phase I trial of daily PI3Kα inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC).
2014 · Payal Deepak Shah, Shanu Modi, et al. · Journal of Clinical Oncology · 9
A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma
2017 · Kian-Huat Lim, Emma Langley, et al. · Oncotarget · 7
PDF
Mechanisms of resistance to PDGFR inhibition in glioblastoma.
2014 · Sandra Pastorino, Emma J. Langley, et al. · Journal of Clinical Oncology · 6
Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
2019 · Ariella B. Hanker, Joan T. Garrett, et al. · Clinical Cancer Research · 3
PDF
713 Novel protease activatable linker with tumor targeting motifs enhances the retention of cytokine prodrug and active cytokine at disease site and demonstrates improved efficacy in preclinical model
2021 · Emma Langley, Chen Li, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Abstract 4652: Cerebrospinal fluid pharmacokinetics and pharmacodynamics following high-dose erlotinib treatment in brain cancer patients
2014 · Sandra Pastorino, Sandeep C. Pingle, et al. · Cancer Research · 1
Identifying targetable pathways in pancreatic cancer from endoscopic ultrasound-guided fine-needle aspirates (EUS/FNA): Providing a personalized approach to targeted therapy.
2013 · Andrea Wang-Gillam, Sachin Wani, et al. · Journal of Clinical Oncology · 1
Su1909 Evaluation of Phosphorylation Signatures in Suspected Pancreatic Cancer Using Endoscopic Ultrasound-Guided Fine Needle (EUS-FNA) Aspirates: A Feasibility Study
2012 · Sachin Wani, Andrea Wang-Gillam, et al. · Gastroenterology · 1
Sa1520 Comparison of Phosphorylation Signatures in Patients With Suspected Pancreatic Cancer Undergoing Endoscopic Ultrasound-Fine Needle (EUS-FNA) With and Without Malignant Cytology: A Pilot Study
2012 · Sachin Wani, Andrea Wang-Gillam, et al. · Gastrointestinal Endoscopy · 1
Related Editorial from Combination of Two Insulin-Like Growth Factor-I Receptor Inhibitory Antibodies Targeting Distinct Epitopes Leads to an Enhanced Antitumor Response
2023 · Jianying Dong, Stephen J. Demarest, et al.
Supplementary Figure 4 from Combination of Two Insulin-Like Growth Factor-I Receptor Inhibitory Antibodies Targeting Distinct Epitopes Leads to an Enhanced Antitumor Response
2023 · Jianying Dong, Stephen J. Demarest, et al.
PDF
Supplementary Figure 3 from Combination of Two Insulin-Like Growth Factor-I Receptor Inhibitory Antibodies Targeting Distinct Epitopes Leads to an Enhanced Antitumor Response
2023 · Jianying Dong, Stephen J. Demarest, et al.
PDF
Supplementary Figure 5 from Combination of Two Insulin-Like Growth Factor-I Receptor Inhibitory Antibodies Targeting Distinct Epitopes Leads to an Enhanced Antitumor Response
2023 · Jianying Dong, Stephen J. Demarest, et al.
PDF
Supplementary Figure 1 from Combination of Two Insulin-Like Growth Factor-I Receptor Inhibitory Antibodies Targeting Distinct Epitopes Leads to an Enhanced Antitumor Response
2023 · Jianying Dong, Stephen J. Demarest, et al.
PDF
Supplementary Figure 2 from Combination of Two Insulin-Like Growth Factor-I Receptor Inhibitory Antibodies Targeting Distinct Epitopes Leads to an Enhanced Antitumor Response
2023 · Jianying Dong, Stephen J. Demarest, et al.
Figures S1-S10 from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
2023 · Ariella B. Hanker, Joan T. Garrett, et al.
Supplementary Materials from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
2023 · Ariella B. Hanker, Joan T. Garrett, et al.
Table S1 from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
2023 · Ariella B. Hanker, Joan T. Garrett, et al.
Supplementary Figure 1 from Combination of Two Insulin-Like Growth Factor-I Receptor Inhibitory Antibodies Targeting Distinct Epitopes Leads to an Enhanced Antitumor Response
2023 · Jianying Dong, Stephen J. Demarest, et al.
Data from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
2023 · Ariella B. Hanker, Joan T. Garrett, et al.
Works count: 39
Citation count: 325
H-index: 7
I10-index: 5
Year
Topic
Type